Despite there being few drugs specific to TDP-43-specific proteinopathies being under clinical trial, we still lack an FDA-approved and TDP-43-directed therapy to slow or reverse the ALS disease [7]. The gene discussed is TARDBP; the disease is proteostasis deficiencies.